Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J2329 |
Short Description | Inj ublituximab-xiiy, 1 mg |
Long Description | Injection, ublituximab-xiiy, 1mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1E |
Action code | N |
Type of service | 1 |
Effective date | 2023-07-01 |
Date Added | 2023-07-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
73150015006 | J2329 | Inj ublituximab-xiiy, 1 mg | BRIUMVI | TG THERAPEUTICS, INC. | 1 MG | 6 | 1 | 150 | 150 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 1 MG |
HCPCS/CPT Billing Units | 1 |
Total doses ordered | |
Billing Units | 1 |
Drug Details
-
Ublituximab-xiiy injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control), including :
-
clinically isolated syndrome (first episode of neurologic symptoms)
-
relapsing-remitting forms (course of disease where symptoms flare up from time to time)
-
secondary progressive forms (course of disease where relapses occur more often).
-
-
Ublituximab-xiiy injection is in a class of medications called monoclonal antibodies. It works by decreasing the action of immune cells that may cause nerve damage.